INMB · INmune Bio, Inc.

Net income narrowed 44.5% to -$5.4M from -$9.7M, with diluted EPS improving 53.5% to -$0.20 from -$0.43. The swing was supported by the increase in other income, mainly a gain on the settlement of a vendor payable in March 2026. These dynamics highlight non-operating factors aiding the bottom line amid ongoing R&D investments in third-party clinical and preclinical services, drug manufacturing, compensation, legal, patent, regulatory, and overhead costs—primary uses of capital that management expects to continue.

Cash flow from operations improved markedly, using $3.4M versus $6.8M last year. This reduction aligns with the smaller net loss and reflects operational efficiencies, positioning liquidity to support near-term activities despite the biotech model's inherent cash consumption. However, numerous risks and uncertainties surround product candidate development, including clinical trial outcomes and regulatory approvals.

Looking forward, management anticipates operating losses and net cash used in operating activities will increase over the next few years as products advance through development. Research and development expenses are expected to rise significantly with expanded clinical trials, drug manufacturing, and regulatory pursuits. The Company expects to incur significant losses for the foreseeable future, with expenses fluctuating quarter-to-quarter and year-to-year. This trajectory underscores execution risks in advancing candidates via collaborations, strategic relationships, and licensing arrangements, consistent with the Company's strategy. Investors should monitor capital resources, as liquidity remains critical to sustaining operations, satisfying obligations, and pursuing ongoing development amid no near-term revenue visibility.